摘要
目的 系统评价利培酮与氟哌啶醇治疗抽动障碍的有效性和安全性。方法 检索截至2023年8月在维普数据库、中国知网、万方医学数据库、PubMed、Embase和Cochrane Library发表的关于利培酮(观察组)与氟哌啶醇(对照组)治疗抽动障碍的随机对照试验,进行系统评价和Meta分析。2名研究人员利用Cochrane系统评价手册进行偏倚风险评估,使用Rev Man 5.4软件进行数据分析。结果 共纳入23篇研究,涉及1 599例患者。Meta分析显示,观察组患者治疗后不良反应症状量表评分及锥体外系反应、口干、嗜睡/镇静、静坐不能、便秘及体质量增加发生率均低于对照组(P<0.05或0.01);两组患者治疗总有效率、耶鲁综合抽动严重程度量表评分比较,差异无统计学意义(P>0.05)。结论 利培酮与氟哌啶醇均可有效治疗抽动障碍,改善患儿抽动症状,但利培酮的不良反应发生率较低,安全性更高。
Objective To systematically evaluate the effectiveness and safety of risperidone and haloperidol in the treat ment of ticdisorders.Methods Randomized cont rolled trials(RCTs) aboutrisper idone(obser vationg roup) and haloper idol(controlg roup) in the treat ment of ticd isorder s were retrieved from the VIP Database,CNKI,Wanfang Medical Database,PubMed,Embase,and Cochrane Library up to Aug.2023,systematic evaluations and meta analysis conducted.The risk of bias was assessed using the Cochrane Ha ndbook for Systematic Reviews by 2 resea rchers and data analyses were conducted using Rev Man 5.4 software.Results A total of 23 studies were included,involving 1 599 patients.Meta analysis showed that score on the the Treatment Emergent Symptom Scale and the incidences of ext rapy ramida lreactions,dry mouth,lethargy/sedation,akathisia,constipation,and body masgain were lower in obser vation than control group(P<0.05 or 0.01);intergroup differences in total effective rate and score on the Yale Global Tic Severity Scale weren't statistically sig nificant(P>0.05).Conclusion Bothrisper idone and haloper idolcan effectivelyt reat tic disorders and improve tic symptoms in children,but risperidone has a lower incidence of adverse reactions and higher safety.
作者
马昂
张耀东
谷裕
王梦琴
赵小桐
梅道启
Ma Ang;Zhang Yaodong;Gu Yu;Wang Mengqin;Zhao Xiaotong;Mei Daoqi(Children's Hospital Affiliated to Zhengzhou University,Zhengzhou 450018,Henan,China;不详)
出处
《临床心身疾病杂志》
CAS
2024年第2期18-24,共7页
Journal of Clinical Psychosomatic Diseases
基金
河南省医学科技攻关联合共建项目(编号LHGJ20200613)。
